Answers are grounded in this paper and cite their sources.
Reactive astrocytes have emerged as important components of the brain metastasis niche, yet a state-resolved framework for metastasis-associated astrocyte biology is still lacking. Here, we integrate single-cell and spatial transcriptomics across syngeneic breast, lung and melanoma models of brain metastases to define a state-resolved astrocyte landscape. We identify recurrent tumor-associated astrocyte states shared across tumor origins, map their spatial distribution, and find that a subset, which we term AST-BrM, becomes selectively reprogrammed at the tumor-microenvironment interface, supporting niche-coupled organization rather than a diffuse brain-wide reactive response. AST-BrM defines distinct metastasis-associated astrocyte states at the peritumoral interface, distinguishes them from homeostatic-like astrocytes beyond generic inflammatory activation, and resolves into two therapeutically actionable programs: an AP-1-high axis and a STAT3+/HOPX+-associated axis. Genetic and pharmacologicall perturbations establish functional relevance, and an AP-1/c-FOS-driven signature is associated with clinical outcome. Together, these findings define conserved, spatially organized and actionable astrocyte programs that drive brain metastasis progression.
No takes yet. Share an insight, caveat, or question.
Hernández-Oliver et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: